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Public health genomics is a multidisciplinary field that uses the effective and responsible 
translation of genome-based knowledge and technologies to improve population health. 
Public health genomics uses population-based data on genetic variation and gene-
environment interactions to develop evidence-based tools for improving health and 
preventing disease. Since 1998, the Office of Genomics and Disease Prevention has 
been at the leading edge of this development in the United States and internationally. In 
2006, CDC changed the name of the office to the “National Office of Public Health 
Genomics (NOPHG)” to better reflect the focus on public health.  NOPHG provides 
national public health leadership while building partnerships with other federal agencies, 
public health organizations, professional groups, and the private sector. 
 
Genomics has the potential to provide insights into why some people get sick from 
certain infectious agents, environmental exposures, and behaviors, while others do not.  
Better understanding of the gene-environment interactions that contribute to health and 
disease will help to identify more effective ways to prevent and treat diseases. 
 
Most human diseases—especially common diseases, like cancer and diabetes—result 
from interactions of genetic factors with modifiable environmental and behavioral factors.  
Very few diseases can be attributed to single genes.  Calling a disease genetic implies 
that no environmental or behavioral interventions exist, and that biology is destiny.  
Conversely, calling a disease environmental ignores the influence of genetic variation on 
disease susceptibility, progression, and response to treatment. 
 
Both nature and nurture are important.  The way genes interact with each other and with 
environmental factors to cause disease, however, is largely unknown.  Clinical and 
epidemiologic studies are needed to identify and better characterize genetic and 
environmental factors and their interactions.  This new knowledge will lead to more 
effective ways to prevent disease and improve health. 
 
Although public health has used genomics in newborn screening programs since the 
1960’s, future genomic applications will require broader program models.  While the 
accelerating rate of genomic discoveries is exciting, immense gaps currently exist in the 
knowledge needed for successful translation of these discoveries into population health 
benefits.  This translation gap calls for public health leadership in shaping the agenda for 
applied research, policy development, and practice.   
 
Anticipating the potential of genomic research for improving population health, CDC 
developed a strategic plan and formed the Office of Genetics and Disease Prevention in 
1997.  The office was renamed the Office of Genomics and Disease Prevention (OGDP) 
in 2003, and this year, as mentioned, the name was changed to the National Office of 



















1. Integrate genomics into public health research. 
2. Assess the role of family history in risk assessment and disease prevention. 
3. Evaluate the use of genetic tests for population health. 
 
1. Integrate Genomics into Public Health Research  
 
CDC is recognized around the world for conducting public health investigations of health 
problems and emergencies and, by doing so, improving people’s daily lives.  Collecting 
and analyzing human genomic data in public health investigations has the potential to 
enhance the ability to understand variation in disease outcomes, characterize 
environmental exposures more accurately, and refine public health interventions such as 
vaccination, chemoprophylaxis, exposure reduction, and health promotion. 
 
2. Assess the Role of Family History in Risk Assessment and 
Disease Prevention 
 
Family history is known to be a risk factor for many chronic diseases including coronary 
heart disease, stroke, cancer, and diabetes.  These common diseases result from the 
interactions of multiple genes with multiple environmental factors in complex patterns 
that, despite progress in sequencing the human genome, are not yet well understood.  In 
the meantime, a person’s family health history can be used as a low-cost, low-tech 
“genomic tool” to capture the interactions of genetic, environmental, and behavioral 
factors in determining that person’s disease risk.  A family history assessment is also the 
first step toward identifying families with increased risk who may benefit from genetic 
testing as well as appropriate health education and behavior modification strategies. 
 
3. Evaluate the Use of Genetic Tests for Population Health 
 
More than 1,000 genetic tests are currently available for clinical testing.  Most are used 
for diagnosis of rare single-gene disorders and a few for newborn screening.  A growing 
number of genetic tests may have population-based applications, such as determining 
the risk of developing a disease or condition in the future (e.g., predictive testing for 
breast cancer) and identifying genetic variations that can influence response to 
medicines (pharmacogenomics).  These genetic tests have the potential for broad public 
health impact, and concerns have been raised about the need for pre- and post-market 




Current Priorities Related to Goals 
 
• Using the National Health and Nutrition Examination Survey (NHANES) III, analyze 
and publish data on the prevalence of the top 100 genetic variants of public health 
significance, and correlate genetic variation with multiple indices of health status in 
the U.S. 
• Test a CDC family history tool that will be used for prevention of 6 common chronic 
diseases. 
• Evaluate a model process for systematic assessment of genomic applications in 
translation from research to practice (Evaluation of Genomic Applications in Practice 
and Prevention—EGAPP initiative). 
  
Major Accomplishments Related to Goals and Priorities 
 
1. Integrate Genomics into Public Health Research  
 
National Health and Nutrition Examination Survey (NHANES) III 
 
The National Health and Nutrition Examination Survey (NHANES) is a nationally 
representative survey of the U.S. population conducted by CDC’s National Center for 
Health Statistics. The NHANES database includes thousands of data points on survey 
participants, including demographic, health history and health behavior characteristics; 
physical and physiological measurements; and detailed nutritional and biochemical 
analyses. During the second phase of NHANES III (1991–1994), white blood cells were 
used to create a DNA bank. 
 
A CDC-NCI working group of epidemiologists, geneticists, and laboratory scientists is 
conducting a collaborative study for determining the prevalence of selected genotypes of 
public health importance for variants in six major pathways using DNA from  
NHANES III:  
• Nutrient metabolism;  
• Immune and inflammatory responses;  
• Activation and detoxification pathways;  
• DNA repair pathways;  
• Hemostasis and renin/angiotension pathways; and 
• Developmental pathways.  
 
The National Cancer Institute has completed the genotyping work.  Data from this study 
will provide the first-ever national genotype prevalence estimates for the United States.  
Such data are important for interpreting the results of studies of gene–disease 
associations and gene–environment interactions. Establishing the prevalence of gene 
variants known to interact with specific environmental factors provides an important 
foundation for developing and assessing the potential impact of environmental 
interventions. 
 
Major Accomplishments Related to NHANES 
 
1. Completed genotyping of more than 80 genetic variants in approximately 7,300 
NHANES III specimens in July 2006 through partnership with NCI. 
2. CDC-NCI Working Group developed a collaborative research plan to investigate 
genotype-phenotype correlations in multiple health outcomes such as asthma, 
diabetes, obesity, and selected infectious diseases. 
3. CDC-NCI Working Group Analytic Committee developed new statistical methods to 
analyze genetic data from studies using complex survey design such as NHANES III.  
4. CDC-NCI Working Group submitted a successful proposal in March 2006 to extend 
the collaborative project to genotype variants in an additional 100 genes of public 
health importance and assess genotype-phenotype correlations for a number of 





Develop a Knowledge Base on Genomics and Population Health:  Human Genome 
Epidemiology (HuGE) 
 
Human genome epidemiology (HuGE) is the basic science of translation from gene 
discovery to clinical and public health practice. The HuGE Network (HuGENet) is a 
global collaboration of individuals and organizations that bridges the fields of genetics, 
medicine and public health to promote harmonization, systematic review and synthesis 
of population-based data on genetic factors in health and disease.    
 
Major Accomplishments Related to HuGENet 
 
1. Established an international network to promote translation of knowledge and 
technologies into public policies, programs and services for the benefit of public 
health. The Genome-based Research and Population Health International Network 
(GRaPH-Int, http://www.graphint.org/) was launched at the 4th International DNA 
Sampling Conference in Montreal in June 2006.  
2. Curates the HuGE Published Literature database (HuGE Pub Lit), a continually 
updated and accessible knowledge base on the World Wide Web that tracks the 
growing published literature of human genome epidemiologic studies. The system 
contains more than 23,000 abstracts and is currently undergoing an extensive 
remodeling and upgrade to improve searching and add new capabilities. 
3. Established additional hubs in Cambridge (UK), Ottawa (Canada), and Ioannina 
(Greece). 
4. Published a “roadmap” in Nature Genetics for the development of a “network of 
investigator networks” to capture and curate unpublished data, conduct meta-
analysis, provide data for policy development and identify research gaps. 
 
Seed Funding for Public Health Genomics Research 
 
In March 2006, NOPHG announced the availability of seed funding for innovative CDC 
projects that integrate genomics into pubic health research and programs.  Thirty-two 
proposals were received and eleven were selected, with priority given to those with 
potential to demonstrate health impact within two years.  The following descriptions 
provide information about 2006 seed funding recipients. 
 
Genetic Predictors of Developing Hemolytic-Uremic Syndrome among persons 
infected with Shiga toxin-producing Escherichia coli (STEC) 
Principal Investigators: Frederick J. Angulo and Linda J. Demma (NCID) 
 
Escherichia coli O157:H7 and other Shiga toxin-producing enterohemorrhagic E. coli 
(STEC)are estimated to cause over 110,000 illnesses, 3000 hospitalizations, and 90 m 
deaths each year in the U.S. Approximately 8% of persons infected with E. coli O157 
develop hemolytic-uremic syndrome (HUS). HUS is associated with substantial morbidity 
and mortality, with case fatality rates as high as 5%; HUS is the leading cause of renal 
failure in children. This project will apply genomic methods to determine host factors 






Microarray Analyses of MHC Genetic Variations in Diisocyanate-induced 
Occupational Asthma 
Principal Investigators: Michael I. Luster( NIOSH), Berran Yucesoy (NIOSH),  Victor J. 
Johnson( NIOSH), and Eugene Demchuk (ATSDR) 
 
Diisocyanates are the most common cause of occupational asthma from low-molecular 
weight chemicals, still causing disease in 5-15 % of chronically exposed workers despite 
improved industrial hygiene efforts. With the recent development of genotype 
microarrays we are now capable of rapidly examining a large number of variants in the 
highly relevant MHC region in a case-control study of exposed workers.  The results 
could be used to assess the genetic contribution in the risk of OA, identify the most 
susceptible (genetic) populations and apply relevant information to the risk assessment 
process by determining safe exposure levels for the most susceptible groups of workers. 
 
Maternal Smoking, Polymorphisms of Genes Involved with Metabolism of  
Tobacco Smoke, and Risk for Gastroschisis and Anorectal Atresia/ Stenosis in the 
National Birth Defects Prevention Study 
Principal Investigators: Margaret A. Honein (NCBDDD), Mary Jenkins (NCBDDD), 
Margaret (Peg) Gallagher (NCEH), Sonja A. Rasmussen (NCBDDD), Patricia Richter 
(NCCDPHP), Robert Merritt (NCCDPHP) 
 
Gastroschisis and anorectal atresia/stenosis are two common, major birth defects. 
Gastroschisis, a herniation of the intestines through a defect in the abdominal wall, 
affects approximately 3.7 infants per 10,000 US births; anorectal atresia/stenosis, the 
congenital absence or narrowing of the anal or rectal canal, affects approximately 4.8 
infants per 10,000 US births. Both of these birth defects are believed to have a 
multifactorial etiology, including both environmental and genetic risk factors. Because 
some studies have reported maternal smoking as a risk factor for both defects, this 
case-control study will focus on potential interaction of maternal smoking with genes 
involved in metabolizing tobacco smoke (CYP2A6, CYP2B6, CYP2D6, CYP1A1, 
CYP1A2, CYP2E1, GSTT1, NAT1, and NAT2). 
 
Identifying Genetic Determinants of Susceptibility to M. tuberculosis 
Principal Investigator:  Mary Reichler (NCHHSTP) 
 
Tuberculosis continues to be a major global health problem.  Each year 54 million 
people worldwide are infected with Mycobacterium tuberculosis, 8.8 million develop 
clinical disease, and 1.75 million die of tuberculosis. In 1999, CDC’s Division of 
Tuberculosis Elimination launched a prospective multi-site study of epidemiologic, 
immunologic, and immunogenetic correlates of susceptibility to TB among contacts of 
infectious TB patients in a U.S. and Canadian-born study population. A total of 1,947 
contacts have been enrolled in the study to date, with a total planned enrollment of 
2,500. Specimens are being tested for three cytokine surrogate markers, HLA, and a 
dozen candidate gene single nucleotide polymorphisms (SNPs). This proposal seeks to 
1) strengthen laboratory capacity, expanding testing from 18 candidate gene SNPs to all 
33 SNPs with demonstrated associations with tuberculosis or strong biologic plausibility, 
and 2) to build specialized capacity to perform complex analyses, including haplotype 
analysis, while carefully evaluating multiple potential gene-gene and gene-environment 
interactions.   
 
  
Investigation of Immunoglobulin (Ig) GM and KM Gene Polymorphisms in 
Susceptibility to and Pathogenesis of Malaria and HIV in Children and Pregnant 
Women in Kenya 
Principal Investigator: Ya Ping Shi (NCID) 
 
Malaria is a major global public health problem, currently estimated to cause 300-500 
million clinical cases and 1.1-2.7 million deaths annually throughout the world. Sub-
Saharan Africa (SSA) accounts for 90% of all these cases and the disease exerts an 
adverse impact on the health of young children, pregnant women and their unborn 
infants. Previous studies conducted in Kenya, a malaria holoendemic and HIV epidemic 
area, have shown that gene polymorphism of the Fc receptor IIa for Ig (FcgRIIa), which 
determines differential affinity for human IgG subclasses, is associated with 1) high 
density malaria infection in children, 2) malaria infection in HIV positive women, and 3) 
perinatal HIV infection. The specific objectives of the proposed study are 1) to determine 
the association between Ig GM/ KM gene polymorphisms and malaria morbidity, 
including severe anemia, and mortality in children, 2) to determine the association of 
gene polymorphisms of Ig GM/ KM with outcomes of malaria infection in pregnant 
women, including maternal anemia, birth defects, and vertical transmission of HIV, 3) to 
determine the effects of Ig GM/ KM gene polymorphisms on the interaction between 
malaria and HIV-1 infection during pregnancy, and 4) to determine the differential 
interaction between Ig GM gene haplotype profiles and FcgRIIa genotypes and acquired 
antibody responses in relation to the above epidemiological and clinical parameters. 
 
Effectiveness and Cost-effectiveness of Using Family History of Diabetes for 
Population–level Health Promotion 
Principal Investigator: Scott Grosse (NCBDDD)
 
Type 2 diabetes is a growing national health problem because of its rapidly increasing 
incidence and associated health impacts, including premature mortality, disabling 
sequelae, and risk of birth defects in offspring. Family history has been shown to be a 
strong predictor of diabetes risk, which could reflect both genetic risk and shared 
behaviors or environment. This project will develop a decision analytic and cost-
effectiveness model to assess the likely outcomes of health promotion efforts that focus 
on the use of family history information on type 2 diabetes. The two specific aims are: 1) 
to develop a decision analytic and cost-effectiveness model to assess the effects on 
health outcomes and costs of health promotion efforts that focus on the use of family 
history of diabetes; and 2) to use this decision model to assess the effects of targeting 
health promotion efforts based on family history of diabetes on the outcomes and costs 
of: i) individuals with a family history of diabetes, ii) individuals without a family history of 
diabetes, and iii) the overall population of individuals. 
 
Should Genetic Testing Be Used to Guide Warfarin Therapy? An Evidence-based 
Cost-Utility Analysis 
Principal Investigator: Scott Grosse (NCBDDD) 
 
Warfarin is a common, chronically administered oral anticoagulant; 16 million 
prescriptions were dispensed in 2004. Warfarin reduces the risk of thromboembolic 
events by 50-79% in atrial fibrillation (AF) patients, yet is prescribed for only about half of 
the 2 million patients diagnosed with AF in the US each year, due in part to concerns 
about the risk of major bleeding and the challenges of closely monitoring and adjusting 
warfarin therapy.  Recently, variants in the CYP2C9 and VKORC1 genes have been 
  
shown to significantly influence warfarin dose requirements, and in the case of CYP2C9, 
the risk of major bleeds. The use of CYP2C9 and VKORC1 genetic testing has thus 
been proposed to help guide warfarin therapy.  Although the analytic and clinical validity 
of these associations has been established, their clinical utility is just beginning to be 
evaluated. This project will develop a disease-based simulation model and perform a 
cost-utility analysis from multiple stakeholder perspectives to help inform treatment 
decisions and guidelines and reimbursement policies. 
 
Effect of Folic Acid Intake on Blood Folate and Homocysteine Levels in Persons 
Classified by Genotype of Folate-related Genes 
Principal Investigators: Quanhe Yang (NCBDDD), Margaret Gallagher (NCEH), David 
Erickson (NCBDDD), and Karen Steinberg (CoCHP)
 
Abnormalities in the metabolism of folate and homocysteine are associated with 
cardiovascular disease and other conditions that contribute significantly to morbidity and 
mortality in the United States. Recently, researchers have identified several common 
polymorphisms of genes related to folate and homocysteine metabolism, including the 
C677T and the A1298C alleles of 5, 10 methylenetetrahydrofolate reductase (MTHFR), 
the 844ins68 allele of cystathionine-beta-synthase (CBS), and the A66G allele of 
methionine synthase reductase (MTRR). These genetic variants may influence folate 
metabolism and disease risk, and that some of their effects may be mediated by gene-
gene and gene-environment interactions. This study will assess whether the effect of 
folic acid intake on the blood levels of folate and homocysteine varies by genotype of 
folate-related genes, using data and DNA samples from NHANES III. 
 
A Proposal to Evaluate Use of the CDC Web-based Family Healthware™ 
Assessment Tool Among Specific Public Health Program and Project Healthcare 
Providers 
Principal Investigator: Susan True (NCCDPHP)
 
CDC supports a collaborative study set in primary care clinics to determine whether 
family history risk assessment and classification using the Family Healthware™ (FHW) 
tool--an interactive Web-based tool that collects information on personal health 
behaviors, screening, and family health history and offers personalized prevention 
messages--can influence health behaviors and the use of preventive medical services. 
This project will assess provider and consumer receptivity to the use of the Family 
Healthware™ (FHW) tool among providers in the National Breast and Cervical Cancer 
Early Detection Program (NBCCEDP), the Division of Cancer’s Colorectal Cancer (CRC) 
demonstration project, and the CDC-funded WISEWOMAN programs. Outcomes from 
this proposal will be used to inform research on expanding use of FHW into community 
health settings. 
 
An Early Childhood Mortality Study Using a Newborn Blood Spot Screening Test 
for Severe Combined Immunodeficiency Disorder (SCID) 
Principal Investigators: Barbara Adam and Robert Vogt (NCEH), Richard Olney 
(NCBDDD), Franco Scinicariello (ATSDR), Chin-Yih Ou (NCHSTP)
 
Severe Combined Immunodeficiency Disorder (SCID) is a group of genetic conditions 
characterized by profound defects in both cellular and humoral immunity.  Caused by the 
nearly complete failure to develop functional T-cells, SCID leads to severe bacterial and 
viral infections; without treatment, affected infants usually die within a year of birth.  NIH 
  
and CDC have developed assays to detect profound T-cell lymphocytopenia by testing 
dried blood spots. Both assays use realtime PCR to measure T-cell recombination 
excision circles (TREC), the episomal circular DNA that is excised from T-cells when 
their V-genes recombine with the constant region genes of the T-cell receptor. The goals 
of this proposal are: 1) to establish authoritative methods for the standardization of the 
TREC assay to foster its systematic translation to public health newborn screening; 2)  to 
determine the extent to which SCID contributes to early childhood mortality; and 3)  to 
establish an ongoing partnership with the Newborn Screening Program in the California 
Department of Health Services to facilitate the investigation of other occult contributors 
to early childhood mortality.  
 
Osteoporosis: A Multi-determinate Approach to Prevention: Implications for the 
CDC Health Protection Goal of Living Better and Longer 
Principal Investigator: Anne Looker (NCHS)
 
Osteoporosis is a major cause of morbidity in the elderly. Inherited factors are important 
determinants of peak bone mass, although the influence of genetic factors on bone 
turnover and changes in bone mass with aging is less clear. Over the past 20 years, 
several candidate genes have been associated with bone mineral density (BMD); 
however, most studies have been conducted on relatively small convenience samples 
and few have examined the role of candidate genes on bone loss or fracture occurrence. 
This study will help fill these gaps by examining the relationship between these 
endpoints and two candidate genes (low-density lipoprotein -receptor related protein 5 
(LRP5) gene (6), and the 116 T/G (Ser37Ala) polymorphism of the bone morphogenetic 
protein 2 (BMP2) gene (7) in a very large, community-based sample. The study takes 
advantage of an existing relationship with Kaiser Permanente of San Diego. 
 
2. Assess the Role of Family History in Risk Assessment and 
Disease Prevention 
 
Beta Version of Family Healthware™  
 
Family history is known to be a risk factor for many chronic diseases—including 
coronary heart disease, cancer, and diabetes—but it is underutilized in preventive 
medicine. To facilitate the systematic collection, interpretation, and use of family health 
history, the CDC has developed a new, interactive, Web-based family history screening 
tool.  Family Healthware™ was developed by a multi-disciplinary team with support from 
a commercial communications firm and a software development company. Part of the 
development effort included assessing family history tools currently used or being 
developed and identifying key design principles for a new tool, as well as developing 
criteria for selecting diseases to include in the tool. Qualitative and quantitative formative 
research on lay understanding of family history and genetics helped shape the tool’s 
content, labels, and messages. Lab-based usability testing helped refine messages and 
tool navigation.  
 
Family Healthware™ assesses familial risk for 6 diseases (coronary heart disease, 
stroke, diabetes, and colorectal, breast, and ovarian cancer) and provides a 
personalized “prevention plan” for lifestyle changes and screening. The tool collects data 
on health behaviors, screening tests, and disease history of a person's first- and second-
degree relatives. Algorithms in the software analyze the family history data and assess 
  
familial risk. A second set of algorithms uses the data on familial risk level, health 
behaviors, and screening to generate personalized prevention messages. The tool is 
being evaluated by three academic centers, which are using a network of primary care 
practices in turn; to determine if prevention messages tailored to familial risk will 
motivate people to change lifestyle or screening behaviors.  
  
Family History Controlled Clinical Trial 
  
The University of Michigan School of Medicine, Evanston Northwestern Healthcare 
Research Institute, and Case Western Reserve University School of Medicine have been 
funded by CDC to collaborate on a study, set in primary care practices, to assess the 
clinical utility of Family Healthware™.  The purpose of this study is to determine whether 
family history risk assessment, stratification, and personalized prevention messages 
influence health behaviors and use of medical services.  The study will consist of 
approximately 6,000 patients aged 35-65 years who attend primary care practices that 
are part of research networks affiliated with the three research centers.  The 
practices are randomized into two groups.  Patients in Group 1 complete a pre-test and 
Family Healthware™ and receive the report with the familial risk assessment and 
personalized prevention recommendations. After six months, Group 1 patients complete 
a post-test.  Patients in Group 2 complete the pre-test and receive standard prevention 
messages for the same diseases.  After 6 months, Group 2 patients complete the post-
test and Family Healthware™.  The pre- and post-test includes assessment of risk 
factors, use of medical services (especially preventive services), interest in modifying 
health behaviors, risk perceptions, etc.  The analysis will compare changes in health 
behaviors between patients in Groups 1 and 2 and will also examine differences by 
familial risk strata. The study began enrolling patients in December 2005 and is 
expected to be completed by October 2007. Results from the study and others will be 
used to modify the tool for use as PC-based software for the general public and as a 
component to new or existing electronic medical records and decision support systems 
for preventive medicine. 
  
Material Transfer Agreements (MTAs) 
  
In addition to the study described above, CDC is making the beta version of Family 
Healthware™ available for research and further pilot testing.   Interested researchers 
can view the software on a password-protected Web site for a limited time after signing a 
confidentiality disclosure agreement.  Those who are interested in obtaining a copy of 
Family Healthware™ for research purposes can establish a Materials Transfer 
Agreement (MTA) with CDC and receive a copy of the software.  To date we have 
established 2 MTAs, one with an academic partner and another with a federal agency.    
  
Surgeon General’s Family History Initiative Resource Packets 
  
As part of the Surgeon General’s Family History Initiative, CDC developed a resource 
packet for state health departments.  The packets contained case studies, fact sheets, 
PowerPoint presentations, a poster, a list of on-line resources, brochures, and 
suggestions for promoting family history in communities.  The packets were distributed in 
November 2005 to coincide with the Surgeon General’s focus on Thanksgiving as 
National Family History Day, and the materials have continued to be useful educational 
tools in 2006. 
 
  
Major Accomplishments Related to Family History 
 
1. Completed quantitative and qualitative formative research on lay understanding of 
family history and genetics to shape content, labels, and messages in Family 
Healthware™ tool. 
2. Completed lab based usability testing to refine messages and tool navigation. 
3. Developed Family Healthware™ tool that assesses familial risk for 6 diseases 
(coronary heart disease, stroke, diabetes, and colorectal, breast, and ovarian 
cancer). 
4. Study of Family Healthware™ tool underway at three academic centers to evaluate 
the effectiveness of the tool for motivating health behaviors and use of medical 
services based on familial risk factors (completion of study scheduled for October 
2007). 
5. Filed for patent for Family Healthware™. 
6. Engaged all state health departments in the Surgeon General’s Family History 
Initiative by providing them with information and resources that will allow them to 
participate in future activities. 
 
3. Evaluate the Use of Genetic Tests for Population Health 
 
As genetic tests with potential for public health impact increase in number and 
complexity, timely and reliable information that helps healthcare providers and 
consumers use genetic tests appropriately is urgently needed.  A coordinated process is 
needed to synthesize currently available data on specific genomic applications and 
clearly identify gaps in knowledge as well as the studies needed to resolve them. 
 
To address this need, the National Office of Public Health Genomics launched the 
Evaluation of Genomic Applications in Practice and Preventions (EGAPP) model project 
in 2004.  The EGAPP initiative aims to develop and evaluate a coordinated, systematic 
process for assessing genomic applications (i.e., genetic tests and other applications of 
genomic technology) in transition from research to clinical and public health practice.   
 
EGAPP Working Group  
 
A CDC-wide and HHS interagency Steering Committee provided early guidance on 
development of project objectives and also selected members of the independent, non-
federal, multi-disciplinary EGAPP Working Group in April, 2005, after a national 
recruitment.  The roles of this 13-member Working Group 
(http://www.cdc.gov/genomics/gtesting/EGAPP/group.htm) are to establish methods and 
process for evidence reviews, identify, prioritize and select topics; monitor the review 
process, and develop conclusions and recommendations based on the evidence.  An 
important objective is to provide clear linkage between the scientific evidence developed 
and the recommendations and information subsequently disseminated.  Supported by 
project staff and consultants, the EGAPP Working Group meets three times per year, 
and the work of the Methods, Products, and Topics Subcommittees continues between 
meetings by teleconference.  
   
Evidence Reports  
Through an Interagency Agreement between CDC and the Agency for Healthcare 
Research and Quality (AHRQ), three evidence reviews will be completed by AHRQ 
  
Evidence-based Practice Centers (EPCs) in 2006; two more EPC-based evidence 
reviews are being initiated, to be completed in 2007.  Other models for evidence review 
are also being utilized to investigate the feasibility and quality of more targeted reviews 
completed on a shorter timeline. 
 
EGAPP Products  
Primary products of the EGAPP initiative will include evidence reports on specific tests; 
published summaries of the evidence reports; and published recommendations of the 
EGAPP Working Group based on the evidence reports.  Secondary products will consist 
of shorter and less technical multi-media informational messages developed for specific 
target audiences from the evidence reports and Working Group recommendations.  
Methods for dissemination of the information developed will include Web postings and 
distribution through professional organizations, health plans/payers, and public health 
programs.  
 
Evaluation Plan   
Evaluation of the success of the EGAPP initiative in raising awareness about the 
process and addressing the need of key stakeholder groups for information about new 
genetic tests is critical to understand how to move forward with a sustainable EGAPP-
like process, and to determine its potential impact on the integration of genomics into 
public health and health care.  In collaboration with a contracted evaluation consultant, a 
plan has been developed to survey key stakeholder groups about their awareness of 
EGAPP and their perception of the utility of EGAPP products (e.g., evidence reviews, 
published summaries, Working Group recommendations, informational messages), and 
to identify changes in clinical practice or coverage/reimbursement that might result. 
 
Collaboration between EGAPP and the Centers for Genomics and Public Health   
To maximize the impact of these products, the CDC-sponsored University of Michigan 
and University of Washington Centers for Genomics and Public Health (CGPH) are 
collaborating with this project to engage stakeholders and to develop strategies for 
translating and disseminating informational messages based on evidence reports and 
EGAPP Working Group recommendations. The University of Washington CGPH has 
developed Web pages that provide background information on genetic testing and the 
process of evidence review.  The Michigan CGPH developed the Stakeholder Advisory 
Group for EGAPP (SAGE), with feedback going directly to the EGAPP Working Group 
through the Products Subcommittee.  
  
Moving Toward a Sustainable Process   
By the end of 2006, the EGAPP Steering Committee and the EGAPP Working Group will 
begin to consider the products and knowledge gained by the project, in order to provide 
recommendations regarding the design and support of a sustainable EGAPP-like 
assessment process. 
 
Major Accomplishments Related to EGAPP 
 
1. EGAPP Working Group meetings and subcommittee teleconferences well attended 





2. Completed evidence reports on three applications of genomic technology: 
• Testing for Cytochrome P450 Polymorphisms in Adults with Depression 
Treated with Selective Serotonin Reuptake Inhibitors (SSRIs) 
• Testing for Hereditary Nonpolyposis Colorectal Cancer in Newly Diagnosed 
Colorectal Cancer Patients and Their Families 
• UGT1A1 Testing for Patients with Colorectal Cancer Treated with Irinotecan 
3. Completed fourth evidence report on Genomic Tests for Ovarian Cancer Detection 
and Management through collaboration between CDC’s Division of Cancer 
Prevention and Control and the EGAPP Project. 
4. Completed development of recommendations based on two of the four completed 
evidence reports, with finalization of recommendations based on the two pending 
reports. 
5. Comprehensive plan to obtain feedback from stakeholders completed, received IRB 
exemption, has been posted for comment in the Federal Register and is pending 
OMB review and approval.  
6. Approval pending from HHS for a waiver request for an independent web site for the 
EGAPP Working Group products - egappreviews.org. 
7. Three additional topics selected for review: 
• Impact of Gene Expression Profiling Tests on Breast Cancer Outcomes 
• Use of Genomic Profiling to Assess Risk for Cardiovascular Disease and 
Identify Individualized Prevention Strategies  
• Screening for CYP450 Polymorphisms to Predict Response to Pain 
Management with Codeine 
8. University of Michigan Center for Genomics and Public Health initiated Stakeholder 
Advisory Group for EGAPP (SAGE). 
  
State Examples Related To Goals and Priorities 
 
In collaboration with the Association of Schools of Public Health, CDC established the 
first Centers for Genomics and Public Health at the Universities of Michigan, North 
Carolina and Washington in 2001.  These Centers became hubs of expertise that built 
on and complemented existing university programs and created links with state and local 
health departments.  In collaboration with CDC, these centers completed two web-based 
training programs for public health professionals:   
• Genomics for Public Health Practitioners, describes the application of genomics 
to public health, dispels myths about genomics and identifies challenges in public 
health genomics.   
• Six Weeks to Genomic Awareness was a series of six presentations aimed at 
helping public health professionals understand how genomic advances are 
relevant to their work. 
 
In 2005, the Universities of Michigan and Washington were awarded funding to continue 
their work in public health genomics.  Current objectives are to facilitate the integration of 
genomics by: 
• Providing technical assistance and competency-based training.  
• Collaborating with CDC projects such as the Evaluation of Genomic Applications 
in Practice and Prevention (EGAPP) Project and the Family History Public Health 
Initiative. 
• Disseminating credible and impartial information. 
• Collaborating with public health agencies and other external partners. 
 
In July 2003, CDC established cooperative agreements with the state health 
departments in Michigan, Minnesota, Oregon, and Utah to assist in developing and 
expanding their capacity to integrate genomic tools (e.g., family history assessments) 
and knowledge into state public health programs for improved health outcomes. These 
states are demonstrating that genomics can be successfully integrated into programs by:  
• Establishing infrastructure and collaborations within their state health 
departments.  
• Developing partnerships with CDC, Centers for Genomic and Public Health, and 
other states and partners. 
• Educating the public health workforce. 
• Assessing the integration of genomics into population-based surveillance, for 
example by adding genetic questions to Behavior Risk Factor Surveillance 
System (BRFSS) surveys. 
• Promoting family history as a screening tool to identify high risk populations and 
target prevention messages and collaborating with CDC’s Well Integrated 
Screening and Evaluation for Women Across the Nation (WISEWOMAN) project. 
 
Assess the Role of Family History in Risk Assessment and Disease Prevention 
 
Public Health Problem 
 
Family health history reflects both shared genetic susceptibility and exposure to common 
environmental, behavioral, and cultural factors that may contribute to diseases, such as 
diabetes and heart disease. This information can be used to identify individuals who are 
  
at increased risk for these diseases. Such individuals can then be targeted for preventive 
measures, such as health screening and behavior change strategies.  
 
Family health history is often underutilized in preventive medicine, or it is used 
ineffectively. Certain types of family history information (e.g., relationship of affected 
family member, type of disease, age of diagnosis, and number of affected family 
members and their lineage) should be collected to accurately assess risk. This 
information should be collected, recorded, and updated in patient charts in a way that is 
accessible to physicians. However, this information is often not documented at all, or 
only partial information is documented in the patient charts.     
 
Program Example (Michigan and Utah) 
 
In 2005, NOPHG-funded genomics programs in Michigan and Utah departments of 
health conducted medical chart reviews within clinics in their respective states. The 
purpose of these reviews was to identify whether family health history was being 
recorded and updated in patients’ charts, and to examine the types of information 
recorded, by whom, and through what means.  
 
• The Michigan genomics program collaborated with the Michigan Cancer Registry 
to conduct medical chart reviews in 23 clinics randomly selected throughout 
Michigan.  In all, 853 charts from December 2003 to October 2004 were 
systematically reviewed for the presence or absence of documented information 
on family history of cancer. The reviews revealed that about 83% of charts 
included family history information. Of these charts, 89% included the gender of 
the affected family member, and 82% included the tumor-site of the family 
members’ cancer diagnosis. However, 94% did not have information on the 
family members’ ages at diagnosis.  
 
• The Utah genomics program contracted with the University of Utah School of 
Medicine to conduct medical chart reviews in 12 family practice clinics randomly 
selected from four counties in Utah. In all, about 400 charts from July to 
September 2005 were systematically reviewed.  Documentation of family history 
of chronic health conditions was found in 60% of charts reviewed. This 
information was documented most often using a questionnaire format (39%), or 
in physicians’ notes (34%). Of those charts with family history, 64% included the 
family relationship for each chronic condition reported, 17% included family 
relationship for some conditions, and 18% did not include this information. Of the 
charts with family relationship, 8% included the age of onset for all conditions 
reported, and 18% included this information for some of the conditions reported.     
 
Results and Impacts to Date 
 
The chart reviews conducted by the Michigan and Utah genomics programs showed 
that, although many charts documented family history, important types of information 
were lacking, such as family relationship and age of onset for reported chronic health 
conditions. This information is critical for assessing hereditary risk. Also, the charts did 
not have a standardized approach for recording and updating the family history 
information, nor was there a standard list of diseases for which this information should 
be documented.  
 
  
Key impacts of these chart reviews include: 
  
• The Michigan genomics program is working with the Michigan Cancer Registry to 
improve the documentation and use of family history information by physicians, 
and to increase awareness among patients. Key activities are inclusion of a 
mandatory family health history question in the Michigan Cancer Registry in 
2007, educating physicians on recommended practices, and encouraging 
patients to routinely collect and record their family history information and share 
this information with their physicians.  
 
The success of this project prompted the Michigan genomics program to work 
with an insurance plan, HealthPlus of Michigan, to conduct a second chart review 
in 2005, this time on chronic health conditions. In all, 250 charts from 50 
physicians were reviewed, and showed similar findings on the presence or 
absence of family history information. Another chart review is planned for 2006, 
using a revised data collection tool which has been expanded to include 
questions about physician referrals for genetic services, use of folic acid, and 
birth defects.    
 
• The Utah genomics program, in collaboration with the University of Utah School 
of Medicine, has developed a set of recommendations for family physicians to 
collect and document family history. These recommendations aim to standardize 
this process by providing a list of chronic health conditions for which family 
history information should be documented, and by describing specific information 
to be collected using suggested approaches or tools.  
 
The Utah genomics program is working with the American Academy of Family 
Physicians, Utah chapter, to raise awareness of the chart review results and 
recommendations (mentioned above) among the academy’s membership. In 
2005, the Utah Genomics Program published articles in the membership 





Integrating Genomics into Public Health Investigations:  CDC Influenza Public 
Health Genomics Initiative 
 
The CDC Influenza Public Health Genomics Initiative is a model project to demonstrate 
integration of human genomics into public health investigations.   
 
With the ongoing threat of seasonal influenza and the potential emergence of new, more 
virulent strains of influenza, CDC and its partners are developing an initiative to 
investigate the role of population genetic variation in the epidemiology of influenza 




Improve influenza preparedness by advancing studies of human genetic variation in 
relation to influenza infection.   
 
Anticipated Products and Public Health Impact 
1. Protocols for acquiring DNA and other biologic samples in the epidemic setting, 
including appropriate methods for obtaining informed consent and for sample 
transport, preparation and storage. An “off-the-shelf” protocol will be available for 
immediate use in epidemic settings. 
2. NOPHG has contracted with America’s Health Insurance Plans (AHIP) to develop a 
multi-site DNA bank from patients within group health plans that can be used to 
study the role of genetic factors in influenza disease severity and vaccine 
effectiveness and side effects response to therapy. 
3. NOPHG will host a workshop January 11-12, 2007 to develop priorities for public 
health genomics research in influenza, focusing on the epidemic and managed care 
settings.     
 
Beyond Gene Discovery (BGD) Initiative:  Developing a National Genomic Profile 
for the U.S. Population  
 
In collaboration with public, private and academic partners, CDC will assess population 
genetic variation in the U.S. in relation to health and disease and develop strategies for 
using genetic information to impact health and eliminate disparities among population 
groups.  The NHANES provides the unique national resource for investigating the effects 
of genetic variation on health and will serve as the initial focus of BGD.  Genetic samples 
are available for nationally representative probability samples of approximately 15,000 
persons enrolled in two NHANES.  The survey oversamples the two largest race/ethnic 
minority groups, non-Hispanic blacks and Mexican Americans, along with other 
subgroups of the population.  Information on multiple aspects of health obtained through 
interview, laboratory tests and direct examinations is also available for the NHANES 
participants.  BGD marks the first large-scale effort in the U.S. to coordinate the 
comprehensive identification of the associations among variations in genotype, 
phenotype, and risk factors in a representative sample of the population, laying the 
groundwork for understanding the relation between human genome variation and health 
status. 
  
BGD will offer an opportunity for an unprecedented look at interactions among numerous 
genetic variants, environmental exposures and behavioral factors contained in the 
clinical, biochemical, and metabolic profiles of a large number of people of all ages.  This 
research will enhance the value of many ongoing gene discovery studies, helping to 
translate findings into new targets for prevention, diagnosis, and treatment of common 
diseases.  By measuring the population prevalence of key genetic variants, BGD will 
provide the basis for estimating the numbers of people who may benefit from particular 
genotype-based screening or diagnostic tests, drugs, or other preventive or therapeutic 
interventions.  BGD represents the whole U.S. population, including minority racial/ethnic 
groups.  By taking an inclusive, evidence-based approach to personalized medicine, 
BGD can help address disparities with data instead of oversimplification. 
 
Applying Genomic Applications to Population Health 
 
A new team is being formed in NOPGH to develop and evaluate genomic applications 
that use clinical and genomic information such as familial risk assessment, signs and 
symptoms recognition, and genetic testing to promote the prevention and early detection 
of both traditional genetic disorders and common chronic diseases.  For many years, 
integration of genomic applications into clinical practice has been focused on genetic 
testing for individually rare single gene disorders.  More recently, we are seeing the 
introduction of genomic applications for common chronic diseases such as using genetic 
markers in early identification of cancer or targeting therapies based on genotype that 
optimize response and avoid adverse drug reactions.  With the completion of the human 
genome sequence, we can expect in the coming years the increasingly rapid 
development of new genetic tests – including concurrent testing of multiple genetic 
markers using microarray technologies (i.e., multiplex testing) – that will be used to help 
refine diagnoses, improve risk prediction, and target therapies for both traditional genetic 
disorders as well as common chronic diseases.  In the meantime, there are already 
genomic applications being used to some extent in clinical medicine which could be 
applied at the population level to assess disease risk, influence early disease detection, 
and provide guidance for disease prevention or management.  These applications, 
including familial risk assessment, signs and symptoms recognition, and genetic testing, 
when used as public health strategies, could lead to overall population health benefits.  
Family history is an important tool for identifying individuals and families with genetic 
susceptibility to common chronic diseases such as coronary heart disease, stroke, 
diabetes and most cancers, as well as the rare single gene disorders like cystic fibrosis, 
sickle cell anemia, hereditary forms of breast and colorectal cancer, and 
hemochromatosis. As an integral part of primary care and preventive medicine, familial 
risk assessment has the potential to identify individuals at risk of disease, those with 
subclinical disease, and those who may already be affected but are undiagnosed.   
There are many single gene disorders across the life span that could benefit from early 
disease detection and interventions through a closer partnership between medicine and 
public health.  Many affected persons with genetic diseases such as hereditary 
hemochromatosis (HH), familial hypercholesterolemia (FH), and primary immune 
deficiency disorders, for example, are either missed by the healthcare system or not 
diagnosed early enough for effective and appropriate interventions to work. Thus 
valuable opportunities for disease and disability prevention are lost.  A public health 
approach employing public and provider education about symptom recognition, 
surveillance strategies, screening, and referral to appropriate services, could be used to 
enhance existing health care practice leading to earlier diagnosis of these disorders.   
  
While efforts are underway to examine the validity and utility of genetic tests that are 
being transitioned from research to clinical and public health practice,  there is little being 
done to examine the uptake of specific tests and the outcomes of genetic testing 
services.  There is a need for genetic testing surveillance and applied research in 
primary care to monitor the integration and penetration of genetic testing into the 
healthcare delivery system. Genetic tests for more than 1,200 diseases have been 
developed, with more than 1,000 currently available for clinical testing.  Most are used 
for diagnosis of rare genetic diseases, but a growing number have population-based 
applications, including carrier identification, predictive testing for inherited risk for 
common diseases, and pharmacogenetic testing for variation in drug response.  These 
tests and other anticipated applications of genomic technologies for screening and 
prevention have the potential for broad public health impact.  
The NOPHG team will work with CDC collaborators and external partners to identify the 
genomic applications and diseases that are ready and most appropriate for a public 
health approach.  Activities for the team might include:  
• Developing an internal CDC working group to define the scope and the plan for 
the team’s activities. 
• Seeking appropriate partnerships and input from outside CDC. 
• Assembling background information on diseases that could potentially benefit 
from genomic applications, including familial risk assessment, signs and 
symptoms recognition, and genetic testing.  
• Identifying gaps in knowledge and research needs for implementing these 
genomic applications in clinical practice and public health.  
• Developing a research and evaluation agenda and sponsoring demonstration 
projects that can show the population health benefits of genomic applications.  
• Establishing a network of research centers that might include academia, states, 
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